Spectral Med Inc (EDT.TO) has seen modest gains this week, driven by significant developments in its clinical trials and regulatory efforts.
This week, Spectral Med Inc's stock closed at C$1.38, marking a 1.46% increase for the day and a 2.96% rise over the week. Investors are closely watching the company's progress with its PMX treatment and ongoing submissions to regulatory authorities.
Advertisement
Earn cash back with a smarter spending account
Open a KOHO account and start earning on everyday purchases — no annual fee on the base plan.
Spectral Med Inc
EDT.TO
EDT.TO
Spectral Med Inc
WealthAwesomeMarket cap
$407.85M
52W high
$1.76
52W low
$0.81
1W change
+2.96%
Beta
0.21
Analyst Price Targets
Based on analyst covering EDT
Wall Street analysts forecast EDT stock price to rise 126.6% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$3.15
+126.6% Upside
Current Price
C$1.39
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on EDT's historical volatility
30-Day Vol
26.6%
Annualized
90-Day Vol
32.9%
Annualized
Trend (90d)
-9.0%
Annualized drift
90d Mean
C$1.35
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$1.38 | C$1.25 – C$1.51 |
| 60 trading days | C$1.36 | C$1.20 – C$1.55 |
| 90 trading days | C$1.35 | C$1.15 – C$1.58 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Spectral Med Inc is in a crucial phase of its development pipeline. Recent clinical trial results and regulatory submissions could impact its market position and investor sentiment moving forward.
C$1.38 closing price reflects a 2.96% weekly increase.
With a market cap of about C$408 million, Spectral Med Inc operates in a niche sector but faces financial challenges that may hinder attracting larger investments.
Bull case
The recent submission of the PMA application for PMX to the FDA, along with positive trial results, could open up significant market opportunities. Analysts are optimistic about the potential for growth.
Bear case
Despite the recent gains, the company struggles with a negative return on equity (ROE) and zero profit margins, which could deter risk-averse investors.
Recent Price Action
Advertisement
Spectral Med Inc (EDT.TO) has shown positive price action this week, closing at C$1.38. This reflects a 1.46% increase for the day and a 2.96% rise over the week. The stock has been steady, with a one-month gain of 5.30% and a year-to-date increase of 0.72%, indicating a gradual upward trend in investor sentiment.
Company News and Developments
There haven't been significant news updates this week, but recent headlines highlight important milestones for Spectral Medical. The company announced the submission of its Premarket Approval (PMA) application for PMX to the U.S. FDA on June 25, 2026. This follows positive topline results from the Tigris trial, which showed a 13.9% absolute risk reduction in mortality at 12 months with PMX compared to standard care. These developments are crucial as they could pave the way for potential commercialization and regulatory approval.
Technical Picture
From a technical standpoint, Spectral Med Inc's stock is currently trading just above its 50-day and 200-day moving averages, both at C$1.37, suggesting a stable position in the short to medium term. The stock has a beta of 0.21, indicating lower volatility compared to the broader market. The 52-week trading range for EDT.TO is between C$0.81 and C$1.76, with the current price positioned at approximately 60% of this range. Recent trading volume has been lower than average, with 17,569 shares traded compared to a 20-day average of 43,066 shares, reflecting a volume ratio of 0.72x.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
